Maurice Lobo
4PUBLICATIONS
46CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Oct 08, 2024
Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.Jeffrey S Weber, Mark R Middleton, Georgia Yates
|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.Jeffrey Weber, Michele Del Vecchio, Mario Mandalá
|Jun 12, 2023
First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.Reinhard Dummer, Pippa Corrie, Ralf Gutzmer
|Apr 14, 2023
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.James Larkin, Michele Del Vecchio, Mario Mandalá
Pageof 1
Frequent Collaborators
3 joint publications
James Larkin
3 joint publications
Paolo A Ascierto
3 joint publications
Jeffrey Weber
3 joint publications
Jean-Jacques Grob
2 joint publications
Mark R Middleton
2 joint publications
Mario Mandalá
2 joint publications
Helen Gogas
2 joint publications
Luis de la Cruz-Merino
2 joint publications
Vanna Chiarion-Sileni
2 joint publications
Ivan Marquez-Rodas
